Table 2 Toxicities leading to discontinuation of 1L-2GTKI.
Dasatinib (n = 16 patients) | Nilotinib (n = 10 patients) | Bosutinib (n = 2 patients) | |
|---|---|---|---|
Hematological | |||
(n = 3) | (n = 1) | (n = 1) | |
Cardiovascular | |||
Congestive heart failure (n = 1) | Palpitations and chest pain (n = 1) | ||
Pericarditis (n = 1) | Palpitations, chest pain and hypertension (n = 1) | ||
Peripheral arterial occlusive disease (PAOD) (n = 1) | |||
Pulmonary | |||
Pulmonary arterial hypertension and pleural effusion (n = 1) | |||
Shortness of breath (n = 2) | |||
Gastrointestinal and Hepatic | |||
Gastrointestinal (n = 1) | |||
Hepatic (n = 1) | Hepatic (n = 1) | Hepatic (n = 1) | |
Metabolic | |||
Diabetes (n = 1) | |||
Dermatological | |||
Skin rash (n = 1) | Skin rash (n = 1) | ||
Alopecia (n = 1) | |||
General | |||
Fatigue (n = 2) | Fatigue (n = 1) | ||
Migraine (n = 1) | |||
Other | |||
Retinal hemorrhage (n = 1) | Thyroiditis (n = 1) | ||
Follicular hyperplasia (n = 1) | |||
